Ligand Pharma (LGND) Stock Forecast & Price Target

Compare

830 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LGND Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Ligand

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LGND Stock 12 Month Forecast

Average Price Target

$243.50

▲(24.34% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Ligand Pharma in the last 3 months. The average price target is $243.50 with a high forecast of $275.00 and a low forecast of $220.00. The average price target represents a 24.34% change from the last price of $195.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"100":"$100","144":"$144","188":"$188","232":"$232","276":"$276"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$275.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":243.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$243.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[100,144,188,232,276],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,196.97,202.97230769230768,208.9746153846154,214.97692307692307,220.97923076923075,226.98153846153846,232.98384615384614,238.98615384615385,244.98846153846154,250.99076923076922,256.9930769230769,262.99538461538464,268.9976923076923,{"y":275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,196.97,200.54923076923077,204.12846153846155,207.7076923076923,211.28692307692307,214.86615384615385,218.44538461538463,222.02461538461537,225.60384615384615,229.18307692307692,232.7623076923077,236.34153846153845,239.92076923076922,{"y":243.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,196.97,198.74153846153845,200.5130769230769,202.2846153846154,204.05615384615385,205.8276923076923,207.59923076923076,209.37076923076924,211.1423076923077,212.91384615384615,214.6853846153846,216.4569230769231,218.22846153846154,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":122.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$275.00

Average Price Target$243.50

Lowest Price Target$220.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts' Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)

Joseph Pantginis

H.C. Wainwright

$231

Buy

17.96%

Upside

Reiterated

12/15/25

Promising Developments and Revenue Prospects Reinforce Buy Rating for Ligand Pharma

Annabel Samimy

Stifel Nicolaus

$220→$230

Buy

17.45%

Upside

Reiterated

12/10/25

Stifel Nicolaus Keeps Their Buy Rating on Ligand Pharma (LGND)

Robert Wasserman

Benchmark Co.

$220

Buy

12.34%

Upside

Reiterated

12/10/25

Ligand Pharma's Strong Financial Outlook and Strategic Investments Justify Buy Rating

Yigal Nochomovitz

Citi

$270

Buy

37.87%

Upside

Initiated

12/09/25

Ligand Pharma's Strategic Positioning and Growth Prospects Justify Buy Rating

Douglas Miehm

RBC Capital

$234→$235

Buy

20.00%

Upside

Reiterated

12/09/25

RBC Capital Reaffirms Their Buy Rating on Ligand Pharma (LGND)

Trevor Allred

Oppenheimer

$250→$275

Buy

40.43%

Upside

Reiterated

11/07/25

Ligand price target raised to $275 from $250 at OppenheimerLigand price target raised to $275 from $250 at Oppenheimer

Balaji Prasad

Barclays

$160

Buy

-18.30%

Downside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts' Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)

Joseph Pantginis

H.C. Wainwright

$231

Buy

17.96%

Upside

Reiterated

12/15/25

Promising Developments and Revenue Prospects Reinforce Buy Rating for Ligand Pharma

Annabel Samimy

Stifel Nicolaus

$220→$230

Buy

17.45%

Upside

Reiterated

12/10/25

Stifel Nicolaus Keeps Their Buy Rating on Ligand Pharma (LGND)

Robert Wasserman

Benchmark Co.

$220

Buy

12.34%

Upside

Reiterated

12/10/25

Ligand Pharma's Strong Financial Outlook and Strategic Investments Justify Buy Rating

Yigal Nochomovitz

Citi

$270

Buy

37.87%

Upside

Initiated

12/09/25

Ligand Pharma's Strategic Positioning and Growth Prospects Justify Buy Rating

Douglas Miehm

RBC Capital

$234→$235

Buy

20.00%

Upside

Reiterated

12/09/25

RBC Capital Reaffirms Their Buy Rating on Ligand Pharma (LGND)

Trevor Allred

Oppenheimer

$250→$275

Buy

40.43%

Upside

Reiterated

11/07/25

Ligand price target raised to $275 from $250 at OppenheimerLigand price target raised to $275 from $250 at Oppenheimer

Balaji Prasad

Barclays

$160

Buy

-18.30%

Downside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ligand Pharma

1 Month

xxx

Success Rate

13/18 ratings generated profit

Average Return

+2.23%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +2.23% per trade.

3 Months

xxx

Success Rate

20/31 ratings generated profit

Average Return

+11.53%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.52% of your transactions generating a profit, with an average return of +11.53% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

27/31 ratings generated profit

Average Return

+43.96%

reiterated a buy rating 13 days ago

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 87.10% of your transactions generating a profit, with an average return of +43.96% per trade.

2 Years

xxx

Success Rate

29/31 ratings generated profit

Average Return

+84.08%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.55% of your transactions generating a profit, with an average return of +84.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LGND Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LGND has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. LGND average Analyst price target in the past 3 months is 243.50.

Each month's total comprises the sum of three months' worth of ratings.

LGND Financial Forecast

LGND Earnings Forecast

Next quarter’s earnings estimate for LGND is $1.50 with a range of $1.18 to $1.64. The previous quarter’s EPS was $3.09. LGND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LGND has Performed in-line its overall industry.

LGND Sales Forecast

Next quarter’s sales forecast for LGND is $55.59M with a range of $50.00M to $64.23M. The previous quarter’s sales results were $115.46M. LGND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LGND has Performed in-line its overall industry.

LGND Stock Forecast FAQ

What is LGND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ligand Pharmaceuticals Inc’s 12-month average price target is 243.50.

What is LGND’s upside potential, based on the analysts’ average price target?

Ligand Pharmaceuticals Inc has 24.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LGND a Buy, Sell or Hold?

Ligand Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ligand Pharmaceuticals Inc’s price target?

The average price target for Ligand Pharmaceuticals Inc is 243.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $275.00 ,the lowest forecast is $220.00. The average price target represents 24.34% Increase from the current price of $195.83.

What do analysts say about Ligand Pharmaceuticals Inc?

Ligand Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of LGND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ligand Pharma (LGND) Stock Forecast & Price Target

LGND Analyst Ratings

LGND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ligand Pharma

LGND Analyst Recommendation Trends

LGND Financial Forecast

LGND Earnings Forecast

LGND Sales Forecast

LGND Stock Forecast FAQ

Detailed List of Analyst Forecasts